Aronora, Inc., a clinical-stage biotech poised to revolutionize blood clot treatment and prevention, today announced it has closed an investment from NYBC Ventures, a venture fund established by New York Blood Center.
Aronora, Inc., a clinical-stage biotech poised to revolutionize blood clot treatment and prevention, today announced it has closed an investment from NYBC Ventures, a venture fund established by New York Blood Center.